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Food allergy aﬀ ects roughly 15 million Americans and 
17 million Europeans, most being young children.1,2 
At present, there is no known treatment or cure. 
However, oral immunotherapy (OIT) is a promising 
investigational therapy which aims to produce allergen 
desensitisation through graduated dose exposure to 
an allergen (eg, temporary tolerance from continuing 
controlled exposure to an allergen, which wanes if 
ongoing exposure is withdrawn). Over time, a lasting 
tolerance to incidental allergen ingestion might remove 
the need for continued ongoing exposure.3 
In The Lancet, Katherine Anagnostou and colleagues 
report the results of the STOP II trial,4 a two-step, 
phase 2, unmasked, randomised controlled crossover trial 
of peanut OIT in 99 children aged 7–16 years, inclusive 
of all severities of peanut allergy. In the ﬁ rst phase, 
participants were randomly assigned to receive either 
26 weeks of OIT to 800 mg of peanut protein, or peanut 
avoidance (the standard of care). Both groups then 
underwent a double-blind, placebo-controlled, peanut 
challenge, and in a second phase the control group was 
oﬀ ered the 26 week OIT protocol and challenge. Among 
OIT participants, 91% (95% CI 79–98) were desensitised 
to 800 mg, the equivalent of ﬁ ve peanuts. In terms of 
the trial’s primary outcome, 24 of 39 OIT participants 
were desensitised to 1400 mg of peanut protein (the 
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ISN also supports about 50 continuing medical 
education programmes a year in LMICs, providing 
international experts who supplement local speakers 
and also meet with local health-care leaders—sometimes 
health ministers—to assess needs and opportunities for 
nephrology and work out how ISN can contribute. 
The global outreach programmes are continuously 
assessed and improved using survey data and local 
feedback. They are oversubscribed, and selection for 
funding is based on objective criteria for the relevance of 
the proposal to the needs of the individual, the centre, 
and the country. In 2012, worldwide, ISN supported 
48 fellows, 37 sister centres, 48 continuing medical 
education programmes, 16 educational ambassadors, 
and six research and prevention grants at an aggregate 
cost of just US$1·5 million, representing, in line with 
its mission, every spare dollar in the ISN budget (after 
running costs of the society were covered). The low costs 
are a result of reduced costs of staﬀ  and services in LMICs: 
ISN members gladly volunteer their time as teachers and 
trainers, travel in economy class, and stay in low-cost local 
accommodation, and sister centres and centres hosting 
fellows make creative use of their own budgets to beneﬁ t 
their partners. The distribution of these ISN programmes 
funded in 2012 in Africa is shown in the ﬁ gure. 
ISN will continue to develop these programmes as its 
top priority and will partner with any organisation with 
the same respect for the achievements in nephrology 
care of our colleagues in developing countries, and 
with the same commitment to supporting sustainable, 
transformational capacity building as the ISN. The results 
that the ISN aim for happen when committed LMIC 
leaders work with ISN leaders and volunteers, and when 
everyone involved understands that, although progress 
might be slow, patience and perseverance are rewarded.
The ISN’s model and achievements provide a 
meaningful answer to how medical care in developing 
countries might be improved. We recommend our model 
to other professional medical societies and to individuals 
who want to help make a real and lasting diﬀ erence in 
health care in developing regions of the world. 
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peak dose oﬀ ered in the trial), as compared with none of 
46 participants in the control group (risk diﬀ erence 62%, 
95% CI 43–77). Compared with control participants, 
those completing OIT had a signiﬁ cant 25-fold increase 
of their no observed adverse eﬀ ect level over baseline, 
and their caregivers had a signiﬁ cant improvement 
in quality of life. Adverse eﬀ ects were mild. Only two 
OIT doses induced symptoms needing epinephrine (both 
in the same patient, who withdrew), although 20% of all 
OIT participants reported adverse events.
Previous studies have concluded that OIT can safely 
produce desensitisation to peanut and other allergens 
among selected, but not all, participants. These studies 
have signiﬁ cant methodological concerns, including 
small sample sizes, selection bias (involving referral 
centre populations of older children without past severe 
reactions and with motivated caregivers), and lack of 
control groups or pre-OIT challenge to conﬁ rm that 
the patient still has persistent allergy.5–10 In particular, 
caregiver participation bias might substantially aﬀ ect 
study results, although this is probably an unavoidable 
constraint dictated by limited selection pools. In past 
peanut OIT studies, high proportions of participants 
developed adverse reactions, including anaphylaxis; 
dropout was high; and no mechanism of action for 
the immunological eﬀ ects was clearly identiﬁ ed. 
Moreover, because adverse events have been reported 
at the dose level (the convention for inhalant/venom 
immunotherapy) and not the patient level, the high 
total proportion of all participants experiencing adverse 
reactions has been obscured when spread across several 
thousand total doses. Notably, patients deliberately 
screened to be less reactive by history have experienced 
more severe reactions than baseline during OIT, and 
not all participants achieve desensitisation.6,7,9,11 Poor 
data exist to predict successes from failures. Therefore, 
previous conclusions that OIT is safe and eﬀ ective might 
be somewhat subjective. 
Anagnostou and colleagues have avoided most 
of these methodological concerns. They report 
fewer side-eﬀ ects with little epinephrine use among 
OIT participants, enrolled community participants 
and individuals with previous severe peanut reactions, 
required entry food challenges, and focused on quality 
of life as a key outcome.4 These are substantial changes 
from earlier peanut OIT studies, but a few problems 
with the methods remain, such as lack of masking, 
participation bias (use of a community sample recruited 
through a food allergy advocacy group), a roughly 10% 
dropout, unclear power for the analysis of the quality 
of life outcome, and use of a truncated peak dose 
(1400 mg) with uncertain clinical importance compared 
with other trials that far exceeded this peak dose.4,5,8–10,12
Therefore, the validity and generalisability of past and 
ongoing OIT studies should be questioned, as with any 
early phase research. Although these concerns should 
not diminish the value of the results so far, which are 
exceptionally promising, OIT remains experimental.13 
OIT is not ready for clinical use until the short-term 
eﬀ ects have been comprehensively proven, and the 
long-term side-eﬀ ects, mechanism of action, and 
outcomes are known. Furthermore, a common protocol 
and delivery vehicle should be decided upon, since this 
has varied across studies.4,6,8–10,12 It is unknown if OIT can 
produce lasting tolerance, a key outcome. Although 
one peanut study and one egg study have shown that 
certain participants can withstand a 2 week (peanut) or 
4–6 week (egg) interruption of OIT and remain tolerant, 
these advances are balanced by reports from other OIT 
studies (milk) of participants developing eosinophilic 
oesophagitis or redeveloping the allergy after months 
to years of tolerating therapy.9,11,14,15 Both are unwanted 
outcomes, and highlight issues still to be clariﬁ ed. 
Continued OIT studies are needed, but with larger 
samples that include severely reactive individuals, 
very young patients, and individuals from both the 
community and referral centre settings to encompass 
a robust food-allergic population. Future studies must 
establish if OIT is cost-eﬀ ective, as well as continue to 
explore how OIT aﬀ ects quality of life. Importantly, 
caregiver goals (eg, achieving a cure vs increasing the 
reaction threshold) need to be understood, which might 
need diﬀ erent protocols to be developed if many goals 
exist. Understanding the range and degree of eﬀ ect is 
also paramount. There is poor understanding of the 
degree of heterogeneity in disease phenotype that 
exists across the food-allergic population. However, 
if there is also heterogeneity of treatment eﬀ ect for 
OIT then this must be comprehensively shown so the 
correct populations of food-allergic individuals receive 
the therapy. It would be naive to view OIT as a one size 
ﬁ ts all treatment for food allergy but, on the contrary, 
it would be short-sighted to deem OIT a failure if only a 
small subset of food-allergic individuals beneﬁ t. 
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International comparisons of acute myocardial infarction
Sheng-Chia Chung and colleagues1 report in The Lancet 
that, in their comparison of short-term outcomes in 
patients with acute myocardial infarction, unadjusted 
30-day mortality was more than a third higher in the 
UK than in Sweden during 2004–10. They suggest that 
this diﬀ erence is due largely to the divergent speed of 
implementation of policy initiatives to improve care. 
Chung and colleagues compared the UK data with those 
for Sweden because the two countries have similar health 
systems for, and spending on, acute myocardial infarction, 
but diﬀ usion of evidence-based changes to practice and 
new technologies has been notably quicker in Sweden.
Records for 119 786 patients in Sweden and 391 077 
in the UK were assessed. This fundamental prognosis 
research,2 which used whole-country data, showed 
much higher unadjusted mortality in patients with acute 
myocardial infarction in the UK than in Sweden: 30-day 
mortality was 10·5% (95% CI 10·4–10·6) in the UK and 
7·6% (7·4–7·7) in Sweden. The UK to Sweden standardised 
mortality ratio was 1·37 (1·30–1·45), which suggests 
that more than 11 000 deaths due to acute myocardial 
infarction might have been avoided during the period 
of the study. Importantly, although the diﬀ erence in 
mortality rates decreased over time, mortality was always 
higher in the UK, even in clinical subgroups such as 
those deﬁ ned by troponin concentration or ST-segment 
elevation. After standardisation for the Swedish casemix 
by use of a 17-variable model that took into account 
patients’ risk at baseline, UK 30-day mortality decreased 
by around 3%. This ﬁ nding suggests that factors from the 
point of ﬁ rst medical contact to 30 days from hospital 
admission diﬀ erentially aﬀ ect outcomes.
Chung and colleagues explored what factors might 
account for the international diﬀ erences in mortality. 
Their ﬁ ndings imply that between-country diﬀ erences in 
the use and dissemination of treatments recommended 
in guidelines was an important factor, as they noted that 
in the UK the uptake of primary percutaneous coronary 
In conclusion, although Anagnostou and colleagues 
provide further evidence that OIT is a potential 
treatment for food allergy,4 more high-quality data are 
needed. It is important to understand that OIT research 
cannot be rushed, and is years away from routine clinical 
use. Investigative groups need time to reﬁ ne protocols, 
revalidate data, understand the mechanisms of OIT, and 
minimise adverse eﬀ ects. This must be done without 
added pressure or heightened expectations to quickly 
produce a marketable therapy.
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